<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00590460</url>
  </required_header>
  <id_info>
    <org_study_id>H-9938</org_study_id>
    <nct_id>NCT00590460</nct_id>
    <nct_alias>NCT00058565</nct_alias>
  </id_info>
  <brief_title>Antibody Conditioning Regimen For Allogeneic Donor Stem Cell Transplantation Of Patients With Fanconi Anemia</brief_title>
  <acronym>Mafia</acronym>
  <official_title>Cd45 (Yth-24 and Yth 54) and Cd52 (Campath-1H) Monoclonal Antibody Conditioning Regimen for Allogeneic Donor Stem Cell Transplantation of Patients With Fanconi Anemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Baylor College of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The Methodist Hospital Research Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Center for Cell and Gene Therapy, Baylor College of Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Baylor College of Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to discover whether children and adults with Fanconi anemia (FA)&#xD;
      can be safely and effectively transplanted with Human Leukocyte Antigen (HLA) mismatched (up&#xD;
      to one haplotype), HLA-matched sibling, or unrelated donor stem cells, when leukocytolytic&#xD;
      monoclonal antibodies are the sole conditioning agents (patients receiving an HLA mismatched&#xD;
      transplant will receive Fludarabine as part of the conditioning regimen). Three monoclonal&#xD;
      antibodies (MAb) will be used in combination. Two of them, YTH 24 and YTH 54 are rat&#xD;
      antibodies directed against two contiguous epitopes on the CD45 (common leucocyte) antigen.&#xD;
      They have been safely administered as part of the conditioning regimen for 12 patients&#xD;
      receiving allografts (HLA matched and mismatched) at this center. They produce a transient&#xD;
      depletion of &gt;90% circulating leucocytes. The third MAb is Campath 1H, a humanized rat&#xD;
      anti-CD52 MAb. This MAb has been widely used to treat B cell chronic lymphocytic leukemia&#xD;
      (B-CLL) and more recently has been safely given at this and other centers as part of a&#xD;
      sub-ablative conditioning regimen to patients with malignant disease. Because these MAb&#xD;
      produce both profound immunosuppression and significant, though transient, myelodestruction&#xD;
      we believe they may be useful as the sole conditioning regimen in patients with Fanconi&#xD;
      anemia, in whom the use of conventional chemotherapeutic agents for conditioning produces a&#xD;
      high rate of short and long term toxicity. We anticipate MAb mediated subablative&#xD;
      conditioning will permit engraftment in a high percentage of these patients with little or no&#xD;
      immediate or long term toxicity. Campath IH persists in vivo for several days after&#xD;
      administration and so will be present over the transplant period to deplete donor T cells as&#xD;
      partial graft versus host disease (GvHD) prophylaxis. Additional GvHD prophylaxis will be&#xD;
      provided by administration of the medication FK506.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      If clinically feasible (no aplasia, no active malignancy), the recipients marrow will be&#xD;
      harvested and cryopreserved as a back up for use if non-engraftment/rejection is followed by&#xD;
      failure to undergo autologous reconstitution.&#xD;
&#xD;
      For HLA Mismatched donors, harvested peripheral blood stem cells will be enriched for CD34&#xD;
      cells using the Clinimacs CD34 Reagent system.&#xD;
&#xD;
      Fludarabine will be given as 5 daily intravenous infusions. Campath-1H will be given as 3&#xD;
      daily intravenous infusions and will be followed by Anti-CD45 which will be given as four&#xD;
      daily intravenous infusions that will be completed two days prior to stem cell infusion.&#xD;
      Diphenydramine will be administered intravenously every 4 hours during the period of the&#xD;
      course of each infusion.&#xD;
&#xD;
      Day -8 Campath 1H as per CAGT SOP Fludarabine 30 mg/m2 -7 Campath 1H as per CAGT SOP&#xD;
      Fludarabine 30 mg/m2 -6 Campath 1H as per CAGT SOP Fludarabine 30 mg/m2 -5 YTH 24/54 400ug/kg&#xD;
      over 6 hr Fludarabine 30 mg/m2 -4 YTH 24/54 400ug/kg over 6 hr Fludarabine 30 mg/m2 -3 YTH&#xD;
      24/54 400ug/kg over 6 hr -2 YTH 24/54 400ug/kg over 6 hr -1 -0 Stem Cell Infusion&#xD;
&#xD;
      GVHD prophylaxis will be achieved through positive selection for CD34 resulting in &gt; 3 log T&#xD;
      cell depletion. Previous reports have indicated that there is a low frequency of severe&#xD;
      (Grade II/IV) GvHD after haploidentical transplants if recipients receive stem cell&#xD;
      populations containing &lt;5 x 10e4 CD3 positive T cells. We hope to achieve such levels with&#xD;
      our CD34 enrichment protocol. However, pharmacologic prophylaxis will be added if the CD34&#xD;
      selected product contains more than 5 x 10e4 CD3+ve T cells/kg recipient weight. In addition,&#xD;
      Campath 1H persists in the recipient circulation through the immediate transplant period and&#xD;
      will contribute anti-GVHD activity, in vivo.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    slow accrual&#xD;
  </why_stopped>
  <start_date>July 2001</start_date>
  <completion_date type="Actual">September 2009</completion_date>
  <primary_completion_date type="Actual">September 2009</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Patients With Donor Engraftment</measure>
    <time_frame>100 Days</time_frame>
    <description>Number of patients with engraftment of at least 65% of donor cells 100 days after transplantation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With Graft Failure</measure>
    <time_frame>100 days</time_frame>
    <description>Graft failure is defined as engraftment of less than 65% of donor cells 100 days after transplantation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patients With Treated Related Death</measure>
    <time_frame>100 days</time_frame>
    <description>Number of patients with treated related death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Days to Absolute Neutrophil Count (ANC) of 500/mm3</measure>
    <time_frame>30 Days</time_frame>
    <description>Number of days to Absolute neutrophil count (ANC) of 500/mm3</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Days to Platelet Count of 20,000/mm3 Without Transfusions</measure>
    <time_frame>30 Days</time_frame>
    <description>Number of days to Platelet count of 20,000 / mm3 without transfusions</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patients With Grade II - IV Acute Graft Versus Host Disease (GVHD)</measure>
    <time_frame>100 days</time_frame>
    <description>Number of patients with grade II - IV acute Graft versus Host Disease (GVHD)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients Alive at 1 Year Post Transplant</measure>
    <time_frame>1 year</time_frame>
    <description>Number of patients alive at 1 year post allogeneic stem cell transplant</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patients With Limited Chronic GVHD From Day 100 to 365</measure>
    <time_frame>365 days</time_frame>
    <description>Number of patients with limited chronic GVHD from day 100 to 365</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patients With Extensive Chronic GVHD From Day 100 to 365</measure>
    <time_frame>365 days</time_frame>
    <description>Number of patients with extensive chronic GVHD from day 100 to 365.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patients With Grade III - IV Acute GVHD</measure>
    <time_frame>100 days</time_frame>
    <description>Number of patients with Grade III-IV acute GVHD</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">5</enrollment>
  <condition>Fanconi Anemia</condition>
  <condition>Severe Aplastic Anemia</condition>
  <arm_group>
    <arm_group_label>Single Arm Study: Stem Cell Transplant</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CAMPATH-1H Anti-CD45 Fludarabine Stem Cell Infusion</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>CAMPATH-1H</intervention_name>
    <description>Given intravenous on days -8, -7, and -6</description>
    <arm_group_label>Single Arm Study: Stem Cell Transplant</arm_group_label>
    <other_name>Alemtuzumab</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Anti-CD45</intervention_name>
    <description>Given intravenous on days -5, -4, -3 and -2&#xD;
dose is 400 micrograms/kg</description>
    <arm_group_label>Single Arm Study: Stem Cell Transplant</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fludarabine</intervention_name>
    <description>Given intravenous on days -8, -7, -6, -5 and -4&#xD;
Dose is 30 mg/m2</description>
    <arm_group_label>Single Arm Study: Stem Cell Transplant</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Stem cell infusion</intervention_name>
    <description>Stem cells are infused on day 0</description>
    <arm_group_label>Single Arm Study: Stem Cell Transplant</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Diagnosis of Fanconi Anemia or other suspected DNA breakage/chromosomal instability&#xD;
        syndromes, such as dyskeratosis congenita or Nijmegen breakage syndrome of all ages are&#xD;
        eligible.&#xD;
&#xD;
        Diagnosis of Fanconi anemia confirmed by studies of peripheral blood or bone marrow&#xD;
        sensitivity to mitomycin C or DEB or clinical evidence of other DNA breakage/chromosomal&#xD;
        instability syndrome as determined by genetic testing or clinical diagnosis by a geneticist&#xD;
&#xD;
        Severe aplasia anemia as evidenced by a hypocellular bone marrow and at least 1 of the 3&#xD;
        criteria below: ANC &lt; 500/mm3 Hemoglobin &lt; 10 gm/dl with reticulocyte count &lt; 1% Platelet&#xD;
        count &lt; 50,000/mm3&#xD;
&#xD;
        Availability of an HLA matched or mismatched (up to one haplotype) family member who has&#xD;
        been documented not to have Fanconi anemia or of an unrelated HLA matched stem cell donor.&#xD;
        Fully matched is defined at 6/6 match by high resolution DR based DNA typing.&#xD;
&#xD;
        Life expectancy greater than 6 weeks limited by diseases other than FA&#xD;
&#xD;
        Creatinine 2X normal for age or less&#xD;
&#xD;
        Karnofsky score 70% or more&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Patients with symptomatic cardiac disease, or evidence of significant cardiac disease by&#xD;
        echocardiogram (i.e., shortening fraction less than 25%).&#xD;
&#xD;
        Patients with known allergy to rat serum products.&#xD;
&#xD;
        Patients with a severe infection that on evaluation by the Principal Investigator precludes&#xD;
        ablative chemotherapy or successful transplantation.&#xD;
&#xD;
        Patients with severe personality disorder or mental illness.&#xD;
&#xD;
        Patients with documented HIV positivity.&#xD;
&#xD;
        Pregnant&#xD;
&#xD;
        NOTE: Patients who would be excluded from the protocol strictly for laboratory&#xD;
        abnormalities can be included at the investigator's discretion after approval by the CCGT&#xD;
        Protocol Review Committee and the FDA Reviewer.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Malcolm Brenner, M.B., Ph.D.,</last_name>
    <role>Principal Investigator</role>
    <affiliation>Baylor College of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Methodist Hospital</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Children's Hospital</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <study_first_submitted>December 26, 2007</study_first_submitted>
  <study_first_submitted_qc>December 26, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 10, 2008</study_first_posted>
  <results_first_submitted>July 2, 2012</results_first_submitted>
  <results_first_submitted_qc>July 2, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 9, 2012</results_first_posted>
  <last_update_submitted>April 26, 2018</last_update_submitted>
  <last_update_submitted_qc>April 26, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 24, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Baylor College of Medicine</investigator_affiliation>
    <investigator_full_name>Malcolm Brenner</investigator_full_name>
    <investigator_title>Professor, Director Center for Cell and Gene Therapy</investigator_title>
  </responsible_party>
  <keyword>Allogeneic Stem Cell Transplant</keyword>
  <keyword>Fanconi Anemia</keyword>
  <keyword>Severe Aplastic Anemia</keyword>
  <keyword>fludarabine</keyword>
  <keyword>campath</keyword>
  <keyword>anti-CD45</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fanconi Syndrome</mesh_term>
    <mesh_term>Anemia</mesh_term>
    <mesh_term>Anemia, Aplastic</mesh_term>
    <mesh_term>Fanconi Anemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Alemtuzumab</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Allo Stem Cell Transplant</title>
          <description>Allogeneic Stem Cell Transplant</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Group1</title>
          <description>only one group</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="5"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=5 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 5 and 9 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 10 and 15 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Patients With Donor Engraftment</title>
        <description>Number of patients with engraftment of at least 65% of donor cells 100 days after transplantation</description>
        <time_frame>100 Days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Allogeneic Stem Cell Transplant</title>
            <description>Single Group: Allogeneic Stem Cell Transplant</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Donor Engraftment</title>
          <description>Number of patients with engraftment of at least 65% of donor cells 100 days after transplantation</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With Graft Failure</title>
        <description>Graft failure is defined as engraftment of less than 65% of donor cells 100 days after transplantation.</description>
        <time_frame>100 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Allogeneic Stem Cell Transplant</title>
            <description>Single Group - Allogeneic Stem Cell Transplant</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Graft Failure</title>
          <description>Graft failure is defined as engraftment of less than 65% of donor cells 100 days after transplantation.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patients With Treated Related Death</title>
        <description>Number of patients with treated related death</description>
        <time_frame>100 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Allo Stem Cell Transplant</title>
            <description>Allogeneic Stem Cell Transplant</description>
          </group>
        </group_list>
        <measure>
          <title>Patients With Treated Related Death</title>
          <description>Number of patients with treated related death</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Days to Absolute Neutrophil Count (ANC) of 500/mm3</title>
        <description>Number of days to Absolute neutrophil count (ANC) of 500/mm3</description>
        <time_frame>30 Days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Allogeneic Stem Cell Transplant</title>
            <description>Single Group: Allogeneic Stem Cell Transplant</description>
          </group>
        </group_list>
        <measure>
          <title>Days to Absolute Neutrophil Count (ANC) of 500/mm3</title>
          <description>Number of days to Absolute neutrophil count (ANC) of 500/mm3</description>
          <units>days</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15" lower_limit="14" upper_limit="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Days to Platelet Count of 20,000/mm3 Without Transfusions</title>
        <description>Number of days to Platelet count of 20,000 / mm3 without transfusions</description>
        <time_frame>30 Days</time_frame>
        <population>Participants achieved a platelet count of 20,000 / mm3 without transfusions.</population>
        <group_list>
          <group group_id="O1">
            <title>Allogeneic Stem Cell Transplant</title>
            <description>Single Group: Allogeneic Stem Cell Transplant</description>
          </group>
        </group_list>
        <measure>
          <title>Days to Platelet Count of 20,000/mm3 Without Transfusions</title>
          <description>Number of days to Platelet count of 20,000 / mm3 without transfusions</description>
          <population>Participants achieved a platelet count of 20,000 / mm3 without transfusions.</population>
          <units>days</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16" lower_limit="14" upper_limit="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patients With Grade II - IV Acute Graft Versus Host Disease (GVHD)</title>
        <description>Number of patients with grade II - IV acute Graft versus Host Disease (GVHD)</description>
        <time_frame>100 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Allogeneic Stem Cell Transplant</title>
            <description>Single Group: Allogeneic Stem Cell Transplant</description>
          </group>
        </group_list>
        <measure>
          <title>Patients With Grade II - IV Acute Graft Versus Host Disease (GVHD)</title>
          <description>Number of patients with grade II - IV acute Graft versus Host Disease (GVHD)</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients Alive at 1 Year Post Transplant</title>
        <description>Number of patients alive at 1 year post allogeneic stem cell transplant</description>
        <time_frame>1 year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Allogeneic Stem Cell Transplant</title>
            <description>Single group: Allogeneic Stem Cell Transplant</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients Alive at 1 Year Post Transplant</title>
          <description>Number of patients alive at 1 year post allogeneic stem cell transplant</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patients With Limited Chronic GVHD From Day 100 to 365</title>
        <description>Number of patients with limited chronic GVHD from day 100 to 365</description>
        <time_frame>365 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Allogeneic Stem Cell Transplant</title>
            <description>Single Group: Allogeneic Stem Cell Transplant</description>
          </group>
        </group_list>
        <measure>
          <title>Patients With Limited Chronic GVHD From Day 100 to 365</title>
          <description>Number of patients with limited chronic GVHD from day 100 to 365</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patients With Extensive Chronic GVHD From Day 100 to 365</title>
        <description>Number of patients with extensive chronic GVHD from day 100 to 365.</description>
        <time_frame>365 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Allogeneic Stem Cell Transplant</title>
            <description>only one group</description>
          </group>
        </group_list>
        <measure>
          <title>Patients With Extensive Chronic GVHD From Day 100 to 365</title>
          <description>Number of patients with extensive chronic GVHD from day 100 to 365.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patients With Grade III - IV Acute GVHD</title>
        <description>Number of patients with Grade III-IV acute GVHD</description>
        <time_frame>100 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Allogeneic Stem Cell Transplant</title>
            <description>Single Group: Allogeneic Stem Cell Transplant</description>
          </group>
        </group_list>
        <measure>
          <title>Patients With Grade III - IV Acute GVHD</title>
          <description>Number of patients with Grade III-IV acute GVHD</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>1 year</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Group1</title>
          <description>only one group</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>NCI CTC</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>CNC hemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>NCI CTC</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Jaw Pain</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>AST</sub_title>
                <counts group_id="E1" events="4" subjects_affected="2" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Picorna virus sinusitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Herpes simplex type I</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperkalemia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="2" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Malcolm Brenner, MD</name_or_title>
      <organization>BAYLOR</organization>
      <phone>832-824-4663</phone>
      <email>mbrenner@bcm.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

